NICE Recommends Sobi’s Doptelet for Refractory Primary Chronic ITP

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Sobi’s Doptelet (avatrombopag) for National Health Service (NHS) use in treating adult patients with primary chronic immune thrombocytopenia (ITP), an autoimmune disorder that includes low platelet counts.

The recommendation was based on clinical trial evidence showing that Doptelet, a thrombopoietin receptor agonist, is more effective than placebo at increasing the number of platelets in the blood to a level that meaningfully reduces the risk of bleeding.

The drug’s efficacy compared with other thrombopoietin receptor agonists is uncertain because the drug had only been compared indirectly with those therapies, the agency said.

The list price of a 10-tablet pack of 20 mg Doptelet is more than $760. The negotiated price for NHS use was not disclosed.